This article was downloaded by: [Lulea University of Technology] On: 29 July 2013, At: 12:48 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lsyc20

Novel One-Pot Synthesis of Aziridines Carrying Sydnone Moiety and Their Biological Studies

Jyothi C. Hegde^a, K. S. Girish^a, Adithya Adhikari^a & Balakrishna Kalluraya^a

^a Department of Studies in Chemistry, Mangalore University, Mangalagangthri, Karnataka, India Accepted author version posted online: 01 Feb 2012.Published online: 18 Oct 2012.

To cite this article: Jyothi C. Hegde , K. S. Girish , Adithya Adhikari & Balakrishna Kalluraya (2013) Novel One-Pot Synthesis of Aziridines Carrying Sydnone Moiety and Their Biological Studies, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 43:2, 301-308, DOI: <u>10.1080/00397911.2011.599102</u>

To link to this article: <u>http://dx.doi.org/10.1080/00397911.2011.599102</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>




Synthetic Communications[®], 43: 301–308, 2013 Copyright © Taylor & Francis Group, LLC ISSN: 0039-7911 print/1532-2432 online DOI: 10.1080/00397911.2011.599102

NOVEL ONE-POT SYNTHESIS OF AZIRIDINES CARRYING SYDNONE MOIETY AND THEIR BIOLOGICAL STUDIES

Jyothi C. Hegde, K. S. Girish, Adithya Adhikari, and Balakrishna Kalluraya

Department of Studies in Chemistry, Mangalore University, Mangalagangthri, Karnataka, India

GRAPHICAL ABSTRACT



Abstract A novel series of 5-(3-arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo[4,1,0]hept-4-enes **3a–l** were prepared in a one-pot synthesis by the reaction of 2,3-dibromo-1-(3-arylsydnon-4-yl)-3-arylpropan-1-one **1a–l** and 1,2-diaminoethane. The newly synthesized compounds were screened for their antibacterial and antifungal activity.

Keywords Aziridine; biological activity; one-pot synthesis; sydnone derivatives


INTRODUCTION


Aziridines are simple nitrogen-containing three-membered heterocycles, one of the most valuable classes in organic chemistry, because of their use in syntheses of many nitrogen-containing biologically active molecules.^[1–3] Many naturally occurring aziridine derivatives exhibit antitumor and antibiotic activity.^[4,5]

Sydnones are a well-defined novel class of mesoionic compounds consisting of a 1,2,3-oxadiazole ring system and are valuable synthetic intermediates.^[6] Because of their mesoionic character, they have been widely studied since their discovery. Interest in sydnone derivatives has been encouraged by the discovery that they exhibit various pharmacological activities.^[7,8]

Received March 10, 2011.

Address correspondence to Balakrishna Kalluraya, Department of Studies in Chemistry, Mangalore University, Mangalagangthri, Karnataka, India. E-mail: bkalluraya@gmail.com







Prompted by these observations and in continuation of our research in sydnone chemistry,^[9-12] we studied the mode of addition between 2,3-dibromo-1-(3-arylsydnone-4-yl)-3-arylpropane-1-ones **1** with ethylen diamine. Surprisingly, such reactions resulted in the formation of a hitherto-unreported novel series of aziridines containing a sydnone moiety (Scheme 1). A probable mechanism for the formation of aziridines is outlined in Scheme 2.

RESULTS AND DISCUSSION

The starting material, 2,3-dibromo-1-(3-arylsydnon-4-yl)-3-arylpropan-1-one **1a–l**, was prepared by the bromination of 1-(3-arylsydnone-4-yl)-3-aryl-2-propene-1-one.^[12] These propenones were in turn prepared by the condensation of appropriate

Table 1. Characterization data of 5-(3-arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo[4,1,0]hept-4-enes 3a-1

							Analysis	Analysis (%) found (calculated)	lculated)
Compound	R	Ar	Mol. formula	Yield (%) MP (°C)	MP (°C)	Nature of the solid	С	Н	Z
3a	Н	Phenyl	$C_{19}H_{16}N_4O_2$	57	160-62	Brown shining needles	68.60 (68.67)		16.79 (16.86)
3b	Η	4-Chlorophenyl	$C_{19}H_{15}CIN_4O_2$	63	152-54	Pale yellow crystals	62.11 (62.21)	4.05 (4.09)	15.22 (15.28)
3c	Η	4-Bromophenyl	$\mathrm{C_{19}H_{15}BrN_4O_2}$	63	144-46	Brown powder	55.68 (55.60)	3.60 (3.65)	13.71 (13.65)
3d	Η	3,4-Methylenedioxyphenyl	$C_{20}H_{16}N_4O_4$	56	163 - 64	Brown crystals	63.71 (63.82)	4.19 (4.25)	14.82 (14.89)
3e	CH_3	Phenyl	$C_{20}H_{18}N_4O_2$	64	158-60	Brown shining crystals	69.25 (69.36)	5.15 (5.25)	16.13 (16.18)
3f	CH_3	4-Chlorophenyl	$C_{20}H_{17}CIN_4O_2$	61	182 - 84	Pale yellow crystals	63.17 (63.08)	4.40 (4.46)	14.78 (14.71)
3g	CH_3	4-Bromophenyl	$C_{20}H_{17}BrN_4O_2$	09	177 - 79	Light yellow crystals	56.72 (56.60)	4.07 (4.00)	13.15 (13.20)
3h	CH ₃	3,4-Methylenedioxyphenyl	$C_{21}H_{18}N_4O_4$	69	175-76	Light yellow crystals	64.70 (64.61)	4.55 (4.61)	14.28 (14.35)
3i	-OCH ₃	Phenyl	$C_{20}H_{18}N_4O_3$	65	138–39	Yellow powder	66.17 (66.29)	4.94 (4.97)	15.41 (15.46)
	-OCH ₃	4-Chlorophenyl	$C_{20}H_{17}CIN_4O_3$	58	167 - 69	Brown crystals	60.62 (60.53)	4.21 (4.28)	14.04 (14.12)
3k	-OCH ₃	4-Bromophenyl	$C_{20}H_{17}BrN_4O_3$	64	143-45	Brown powder	54.66 (54.54)	3.82 (3.86)	12.66 (12.72)
31	-OCH ₃	3,4-Methylenedioxyphenyl	$C_{21}H_{18}N_4O_5$	62	155-56	Light brown needles	62.13 (62.06)	4.39 (4.43)	13.72 (13.79)

aldehydes with 3-substituted-4-acetylsydnones.^[12] 3-Substituted-4-acetylsydnone was prepared according to the procedure reported in the literature.^[13]

The reaction between 2,3-dibromo-1-(3-arylsydnon-4-yl)-3-arylpropan-1-one **1a–I** with ethylene diamine **2** in the presence of triethyl amine in ethanol medium resulted in the formation of 5-(3-arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo[4,1,0]hept-4-enes **3a–I**. All the newly synthesized compounds were characterized by spectral and analytical data. The characterization data of the newly synthesized compounds are given in Table 1.

The infrared (IR) spectra of these compounds showed an absorption band around 1754–1765 cm⁻¹ for the carbonyl group of sydnone moiety. The ¹H NMR spectra (300 MHz) (CDCl₃) of aziridine **3g** showed a singlet at δ 2.35 integrating for three protons for the methyl group. The methylene protons at C-2 are found to be magnetically nonequivalent as they are prochiral. The signals corresponding to these two protons appeared as multiplets centered at δ 2.70 and δ 3.44, integrating for one proton each. The methylene protons at C-3 also appeared to be magnetically nonequivalent (diastereotopic) because of the restricted rotation and the signals due to these protons also appeared as multiplets centered at δ 3.21 and δ 3.80, integrating for one proton each. The two methine protons at C-7 and C-6 appeared as two doublets at δ 2.90 and δ 3.30, each integrating for one proton. The *ortho-* and *meta*-protons of *p*-tolyl group appeared as two doublets centered at δ 7.03 and δ 7.21, integrating for two protons each. Similarly the *ortho-* and *meta*-protons of *p*-bromophenyl group appeared as two doublets centered at δ 7.34 and δ 7.40, each integrating for two protons.

Further the mass spectrum [liquid chromatography-mass spectrometry (LCMS)] of this compound showed the $M^+ + 1$ peak and the corresponding isotopic peak at m/z 425/427, consistent with the molecular formula $C_{20}H_{17}BrN_4O_2$. Fragment peak at m/z 367 is due to the loss of -NO and -CO from the molecular ion, which is characteristic of sydnone-containing molecule. Base peak was observed at m/z 91 because of the formation of tropylium cation.

BIOLOGICAL ACTIVITY

The newly synthesized compounds 3a-1 were subjected for in vitro antibacterial and antifungal studies by the cup-plate^[14] method against both Gram-positive and Gram-negative bacteria. Antibacterial activity was determined against *S. aureus* (ATCC-25923) and *K. pneumoniae* and antifungal activity was studied against *A. niger* and *C. albicans* (NCIM-NO. 3100). Ciprofloxacin and ciclopiroxolamine were employed as standard drugs. Dimethyl formamide (DMF) was used as solvent control. Among them, compounds **3c**, **3d**, and **3l** showed considerable antibacterial and antifungal activities. The results of antibacterial and antifungal studies are summarized in Table 2.

CONCLUSION

In conclusion, we studied the reaction of sydnone dibromides with ethylene dibromides to get a novel series of aziridines, namely 5-(3-arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo[4,1,0]hept-4-enes **3a–I**, in a one-pot reaction, and the yields ranged from 53% to 69%.

Compound	Antibacterial activities ^a (diameter of zone of inhibition in mm)		Antifungal activities ^b (diameter of zone of inhibition in mm)	
	S. aureus	K. pneumoniae	A. niger	C. albicans
3c	20	18	20	24
3d	18	22	26	26
3f	14	10	10	14
3g	15	12		10
3h		09	10	16
3j	12	18	20	18
3k	_	_	_	
31	20	22	18	24
Solvent control DMF				
Ciprofloxacin	20	22		_
Ciclopiroxolamine			24	26

Table 2. Antibacterial and antifungal activity data of 5-(3-arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo [4,1,0]hept-4-enes 3a-l

Notes. Diameter of the cup, 5 mm; amount of the sample used, $25 \,\mu g/cup$; and solvent control, dimethyl formamide.

^aCiprofloxacin used as standard.

^bCiclopiroxolamine used as standard.

EXPERIMENTAL

Melting points were determined using the open capillary method and are uncorrected. All compounds were analyzed satisfactorily for C, H, N (Vairo-EL Elementar III model analyzer). Infrared (IR) spectra (KBr pellet) were recorded on a Perkin-Elmer 983 or Jasco Fourier transform (FT) IR 430 spectrophotometer. The ¹H NMR spectra were recorded on a Bruker AC 300 F (300-MHz) NMR spectrometer using dimethylsulfoxide (DMSO- d_6) as solvent and tetramethylsilane (TMS) as an internal standard. The chemical shift values are expressed in δ scale downfield from TMS, and proton signals are indicated as s, singlet; d, doublet; and m, multiplet. Mass spectra of synthesized compounds were recorded on a Jeol JMS-D 300 mass spectrometer or LC/MS (API 3000, Applied Bio systems) operating at 70 eV.

Preparation of 2,3-Dibromo-1-(3-arylsydnon-4-yl)-3-arylpropan-1-one 1a–l

1-(3-Arylsydnon-4-yl)-3-aryl-2-propen-1-ones (0.01 mol) was dissolved in glacial acetic acid (20 ml) by gentle warming. A solution of bromine in glacial acetic acid (30% w/v) was added to it with constant stirring until the yellow color of the bromine persisted. The reaction mixture was stirred at room temperature for 1–2 h. The solid separated was filtered, washed with methanol, and dried. It was then recrystallized from ethanol.

Preparation of 5-(3-Arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo[4,1,0] hept-4-enes 3a-l

A mixture of 2,3-dibromo-1-(3-arylsydnon-4-yl)-3-arylpropan-1-one **1a–1** (0.01 mol), ethylenediamine (0.01 mol), and triethylamine (0.05 mol) was dissolved in 15 ml ethanol by heating. The clear solution was allowed to stand at room temperature for 4–6 days. The progress of the reaction was monitored by thin-layer chromatography (TLC). The solid separated was collected by filtration and recrystallized from ethanol to get pure 5-(3-arylsydnon-4-yl)-7-aryl-1,4-diazabicyclo[4,1,0]hept-4-enes **3a–I** in 53–69% yield.

The characterization data of compounds 3a-l are given in Table 1.

Compound 3a. IR (KBr disc): $\gamma_{(C=0 \text{ sydnone})} 1761 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1605 \text{ cm}^{-1}$. ¹H NMR (300 MHz) CDCl₃, δ , 2.61 (m, 1H, C₂-H); δ 3.05 (d, 1H, C₇-H); δ 3.31 (m, 1H, C₃-H); δ 3.42 (d, 1H, C₆-H); δ 3.48–3.60 (m, 1H, C₂-H); δ 3.68–3.78 (m, 1H, C₃-H); δ 7.1–7.4 (m, 10H, Ar-H). Mass: m/z, 333 (M⁺ + 1) (MF: C₁₉H₁₆N₄O₂).

Compound 3b. IR (KBr disc): $\gamma_{(C=O \text{ sydnone})} 1764 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1602 \text{ cm}^{-1}$. ¹H NMR (300 MHz) CDCl₃, δ , 2.65–2.71 (m, 1H, C₂-H); δ 2.78 (d, 1H, C₇-H); δ 3.08 (m, 1H, C₃-H); δ 3.28 (d, 1H, C₆-H); δ 3.41–3.48 (m, 1H, C₂-H); δ 4.23–4.54 (m, 1H, C₃-H); δ 6.91 (d, 2H, *ortho* protons of *p*-chlorophenyl); δ 7.28 (d, 2H, *meta* protons of *p*-chlorophenyl); δ 7.05–7.40 (m, 5H, Ar-H). Mass: *m*/*z*, 367/369 (M⁺ + 1 & M⁺ + 3 peak) (MF: C₁₉H₁₅ClN₄O₂).

Compound 3c. IR (KBr disc): $\gamma_{(C=0 \text{ sydnone})} 1760 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1594 \text{ cm}^{-1}$. ¹H NMR (300 MHz) DMSO-*d*₆, δ , 2.65–2.74 (m, 1H, C₂-H); δ 2.81 (d, 1H, C₇-H); δ 3.06–3.18 (m, 1H, C₃-H); δ 3.28 (d, 1H, C₆-H); δ 3.35–3.47 (m, 1H, C₂-H); δ 4.31–4.64 (m, 1H, C₃-H); δ 6.91 (d, 2H, *ortho* protons of *p*-bromophenyl); δ 7.32 (d, 2H, *meta* protons of *p*-bromophenyl); δ 7.10–7.30 (m, 5H, Ar-H). Mass: *m/z*, 411/413 (M⁺ + 1 & M⁺ + 3 peak) (MF: C₁₉H₁₅BrN₄O₂).

Compound 3d. IR (KBr disc): $\gamma_{(C=O \text{ sydnone})} 1758 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1598 \text{ cm}^{-1}$. ¹H NMR (300 MHz) DMSO-*d*₆, δ 2.58–2.66 (m, 1H, C₂-H); δ 2.71 (d, 1H, C₇-H); δ 2.96–3.18 (m, 1H, C₃-H); δ 3.31 (d, 1H, C₆-H); δ 3.50–3.60 (m, 1H, C₂-H); δ 4.10–4.35 (m, 1H, C₃-H); δ 4.54 (s, 2H, O-CH₂-O); δ 6.96–7.41 (m, 8H, Ar-H). Mass: *m*/*z*, 377 (M⁺ + 1) (MF: C₂₀H₁₆ClN₄O₄).

Compound 3e. IR (KBr disc): $\gamma_{(C=0 \text{ sydnone})} 1756 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1595 \text{ cm}^{-1}$. ¹H NMR (300 MHz) CDCl₃, δ , 2.32 (s, 3H, CH₃); δ , 2.70 (m, 1H, C₂-H); δ , 2.97 (d, 1H, C₇-H); δ , 3.24 (m, 1H, C₃-H); δ , 3.33 (d, 1H, C₆-H); δ , 3.38-3.52 (m, 1H, C₂-H); δ , 3.76–3.84 (m, 1H, C₃-H); δ , 7.19 (d, 2H, *ortho*-protons of *p*-tolyl); δ , 7.34 (d, 2H, *meta*-protons of *p*-tolyl); δ , 7.12–7.28 (m, 5H, Ar-H). Mass: *m*/*z*, 347 (M⁺ + 1) (MFC₂₀H₁₈N₄O₂).

Compound 3f. ¹H NMR (300 MHz) CDCl₃, δ , 2.28 (s, 3H, CH₃); δ 2.46 (m, 1H, C₂-H); δ 2.80 (d, 1H, C₇-H); δ 3.15 (m, 1H, C₃-H); δ 3.30 (d, 1H, C₆-H); δ 3.46–3.59 (m, 1H, C₂-H); δ 3.60–3.69 (m, 1H, C₃-H); δ 7.15 (d, 2H, o-protons of *p*-tolyl); δ 7.26 (d, 2H, m-protons of *p*-tolyl); δ 7.34 (d, 2H, o-protons of *p*-chlorophenyl); δ 7.54 (d, 2H, m-protons of *p*-chlorophenyl). Mass: *m*/*z*, 381/383 (M⁺ + 1 and M⁺ + 3 peaks) (MFC₂₀H₁₇ClN₄O₂).

Compound 3h. IR spectra (KBr disc): $\gamma_{(C=0 \text{ sydnone})} 1749 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1605 \text{ cm}^{-1}$. ¹H NMR (300 MHz) CDCl₃, δ , 2.25 (s, 3H, CH₃); δ 2.48–2.56 (m, 1H, C₂-H); δ 2.75 (d, 1H, C₇-H); δ 2.90–3.10 (m, 1H, C₃-H); δ 3.40 (d, 1H, C₆-H); δ 3.49–3.68 (m, 2H, C₂-H & C₃-H); δ 4.49 (s, 2H, -O-CH₂-O); δ 7.10 (d, 2H, o-protons of *p*-tolyl); δ 7.25–7.52 (m, 5H, remaining aromatic protons). Mass: *m*/*z*, 391 (M⁺ + 1) (MF C₂₁H₁₈N₄O₄).

Compound 3i. IR spectra (KBr disc): $\gamma_{(C=0 \text{ sydnone})}$ 1753 cm⁻¹, $\gamma_{(C=N)}$ 1589 cm⁻¹. ¹H NMR (300 MHz) CDCl₃, δ , 2.61–2.68 (m, 1H, C₂-H); δ 2.83 (d, 1H, C₇-H); δ 3.23–3.36 (m, 1H, C₃-H); δ 3.41 (d, 1H, C₆-H); δ 3.52–3.58 (m, 1H, C₂-H); δ 3.83 (s, 3H, -OCH₃); δ 4.32–4.65 (m, 1H, C₃-H); δ , 7.06 (d, 2H, *ortho* protons of *p*-anisyl); δ 7.28 (d, 2H, *meta*-protons of *p*-anisyl); δ 7.31–7.53 (m, 5H, Ar-H). Mass: m/z, 363 (M⁺ + 1) (MF C₂₀H₁₈N₄O₃).

Compound 3j. IR spectra (KBr disc): $\gamma_{(C=0 \text{ sydnone})}$ 1759 cm⁻¹, $\gamma_{(C=N)}$ 1593 cm⁻¹. ¹H NMR (300 MHz) CDCl₃, δ , 2.70–2.74 (m, 1H, C₂-H); δ , 2.86 (d, 1H, C₇-H); δ , 3.17–3.20 (m, 1H, C₃-H); δ , 3.31 (d, 1H, C₆-H); δ 3.45–3.50 (m, 1H, C₂-H); δ 3.79 (s, 3H, -OCH₃); δ 4.43–4.79 (m, 1H, C₃-H); δ 6.87 (d, 2H, o-protons of *p*-chlorophenyl); δ 7.07 (d, 2H, *ortho*-protons of *p*-anisyl); δ 7.24 (d, 2H, *meta*-protons of *p*-anisyl); δ 7.38 (d, 2H, m-protons of *p*-chlorophenyl). Mass: *m*/*z*, 397/399 (M⁺ + 1 and M⁺ + 3 peak) (MF C₂₀H₁₇ClN₄O₃).

Compound 3k. IR spectra (KBr disc): $\gamma_{(C=0 \text{ sydnone})} 1757 \text{ cm}^{-1}$, $\gamma_{(C=N)} 1604 \text{ cm}^{-1}$. ¹H NMR (300 MHz) CDCl₃, δ , 2.58–2.64 (m, 1H, C₂-H); δ 2.86 (d, 1H, C₇-H); δ 3.21–3.34 (m, 1H, C₃-H); δ 3.41 (d, 1H, C₆-H); δ 3.48–3.71 (m, 2H, C₂-H & C₃-H); δ 3.91 (s, 3H, -OCH₃); δ 6.90 (d, 2H, *ortho*-protons of *p*-bromophenyl); δ 7.10 (d, 2H, *ortho*-protons of *p*-anisyl); δ 7.31 (d, 2H, *meta*-protons of *p*-anisyl); δ 7.42 (d, 2H, *meta*-protons of *p*-bromophenyl). Mass: *m/z*, 441/443 (M⁺ + 1 and M⁺ + 3 peak) (MF C₂₀H₁₇BrN₄O₃).

Compound 3I. IR spectra (KBr disc): $\gamma_{(C=0 \text{ sydnone})}$ 1758 cm⁻¹, $\gamma_{(C=N)}$ 1595 cm⁻¹. ¹H NMR (300 MHz) CDCl₃, δ , 2.68–2.70 (m, 1H, C₂-H); δ 2.89 (d, 1H, C₇-H); δ 3.01–3.21 (m, 1H, C₃-H); δ 3.34 (d, 1H, C₆-H); δ 3.42–3.54 (m, 1H, C₂-H); δ 3.94 (s, 3H, -OCH₃); δ 4.21–4.54 (m, 1H, C₃-H); δ 4.61 (s, 2H, O-CH₂-O); δ 7.14 (d, 2H, *ortho*-protons of *p*-anisyl); δ 7.42–7.61 (m, 5H, *meta*-protons of *p*-anisyl & Ar-H). Mass: m/z, 407 (M⁺ + 1) (MF C₂₁H₁₈N₄O₅).

ACKNOWLEDGMENTS

The authors thank the head, RSIC, Chandigarh, and CDRI, Lucknow, for spectral and analytical data.

REFERENCES

- Lindstrom, U. M.; Somfai, P. Aminolysis of vinyl epoxides as an efficient entry to N-H vinylaziridines. *Synthesis* 1998, 109.
- 2. Sweeney, J. B. Aziridine: Epoxides' ugly cousins? Chem. Soc. Rev. 2002, 31, 247.
- 3. Hu, X. E. Nucleophilic ring opening of aziridines. Tetrahedron 2004, 60, 2701.

- 4. Remers, W. A. *The Chemistry of Antitumour Antibiotics*; Wiley- Interscience: New York, 1979; vol. 1, p. 242.
- 5. Remers, W. A.; Dorr, R. T. *Alkaloids: Chemical and Biological Perspectives*; S. W. Pelletier, (Ed.); Wiley: New York, 1988; vol. 6, p. 1.
- Hegde, J. C.; Rai, G.; Puranik, V. G.; Kalluraya, B. Exclusive formaton of 1-aryl-3-(5-nitro-2-furyl)-4-aroylpyrazoles via regiospesific 1,3-dipolar cycloaddition of 3-aryl sydnones with α, β-acetylenic ketones. *Synth. Commun.* 2006, *36*, 1285.
- Dunkely, C. S.; Thoman, C. J. Synthesis and biological evaluation of a novel phenyl substituted sydnone series as potential antitumour agent *Bioorg. Med. Chem. Lett.* 2003, 13, 2899.
- Shih, M. H.; Ke, F. Y. Synthesis and biological evaluation of antioxidant activity of sydnonyl substituted thiazidinone and thiazoline derivatives. *Bioorg. Med. Chem.* 2004, *12*, 4633.
- Kalluraya, B.; Rahiman, A. M.; Banji, D. Sydnone derivatives, Part VII: Synthesis of some novel thiazoles and their pharmacological properties. *Arch. Pharm. Med. Chem.* 2001, 334, 263.
- Kalluraya, B.; Rai, G. Robinson's annulation: Synthesis of sydnone containing 3¹-aryl cyclohexenone derivative under solvent free condition. *Synth. Commun.* 2003, 33 (20), 3589.
- Kalluraya, B.; Rahiman, A. M. Synthesis and anti-inflammatory activity of 3-substituted-4-(3-aryloxymethyl-7H-s-triazolo[3,4-b][1,3,4]thiadiazin-6-yl)-sydnones. *Polish J. Chem.* **1997**, *71*, 1049.
- 12. Satheesha Rai, N.; Kalluraya B.; Lingappa, B. Novel one pot synthesis of aziridines containing sydnone moiety. *Synth. Commun.* **2007**, *37*, 2267.
- Kalluraya, B.; Rahaman, A. M.; Banji, D.; Isloor, A. M.; Rai, G. Sydnone derivatives Part-III: synthesis and pharmacological study of 3-aryl-4-(Substituted piperonylidene hydrazine-4-thiazolyl)sydnone. *Indian J. Heterocycl. Chem.* 2000, 9, 217.
- 14. Seely, H. W.; Van Demark, P. J. Microbes in Action: A Laboratory Manual in Microbiology, 2nd ed.; Freeman: San Francisco, 1975; p. 55.